Checkpoint Therapeutics
CKPT
CKPT was delisted on the 29th of May, 2025.
43 hedge funds and large institutions have $11.2M invested in Checkpoint Therapeutics in 2023 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 16 increasing their positions, 10 reducing their positions, and 7 closing their positions.
68% more capital invested
Capital invested by funds: $6.68M → $11.2M (+$4.53M)
60% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 10
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
10% more funds holding
Funds holding: 39 → 43 (+4)
2.64% more ownership
Funds ownership: 18.8% → 21.43% (+2.6%)
1% less call options, than puts
Call options by funds: $493K | Put options by funds: $496K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$788K |
| 2 |
Renaissance Technologies
New York
|
+$361K |
| 3 |
D.E. Shaw & Co
New York
|
+$306K |
| 4 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
+$249K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$143K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$447K |
| 2 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
-$50.1K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$35.6K |
| 4 |
AWM
Apollon Wealth Management
Mount Pleasant,
South Carolina
|
-$23.6K |
| 5 |
Millennium Management
New York
|
-$20.5K |
CKPT Hedge Fund Activity: Q4 2023 in Review
43 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Checkpoint Therapeutics (CKPT) for Q4 2023, worth a combined $11.2M — up 68% from $6.68M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new CKPT positions and 7 closed out — a net gain of 4 holders — while 16 added to existing stakes and 10 trimmed.
The largest buyer was Armistice Capital, adding an estimated $788K. The largest seller was Sabby Management, exiting entirely with an estimated $447K sold.
- 43 institutional investors held Checkpoint Therapeutics (CKPT) as of Q4 2023, up from 39 in Q3 2023.
- Funds reported $11.2M of Checkpoint Therapeutics stock for Q4 2023, up 68% quarter-over-quarter.
- 11 funds opened new Checkpoint Therapeutics positions in Q4 2023 and 7 closed out, a net change of +4 holders.
- The largest Checkpoint Therapeutics buyer in Q4 2023 was Armistice Capital, an estimated $788K added.
- The largest Checkpoint Therapeutics seller in Q4 2023 was Sabby Management, an estimated $447K sold.
Based on aggregated 13F filings for Q4 2023.